Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Return on Equity: 2017-2025

Historic Return on Equity for Akebia Therapeutics (AKBA) over the last 8 years, with Sep 2025 value amounting to -0.45%.

  • Akebia Therapeutics' Return on Equity fell 154.00% to -0.45% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.45%, marking a year-over-year decrease of 154.00%. This contributed to the annual value of 1.74% for FY2024, which is 236.00% down from last year.
  • As of Q3 2025, Akebia Therapeutics' Return on Equity stood at -0.45%, which was up 66.88% from -1.36% recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Return on Equity high stood at 8.45% for Q1 2023, and its period low was -5.78% during Q1 2022.
  • Moreover, its 3-year median value for Return on Equity was 1.48% (2023), whereas its average is 2.11%.
  • In the last 5 years, Akebia Therapeutics' Return on Equity soared by 1,423bps in 2023 and then slumped by 696bps in 2024.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Return on Equity stood at -2.69% in 2021, then surged by 282bps to 0.12% in 2022, then spiked by 136bps to 1.48% in 2023, then dropped by 9bps to 1.39% in 2024, then crashed by 154bps to -0.45% in 2025.
  • Its Return on Equity stands at -0.45% for Q3 2025, versus -1.36% for Q2 2025 and 3.68% for Q1 2025.